Cardiff Oncology gets FDA fast track designation for onvansertib combination in first-line RAS-mutated colorectal cancer
CRDF•The FDA granted Fast Track designation to Cardiff Oncology’s onvansertib combination for first-line treatment of adults with KRAS- or NRAS-mutated metastatic colorectal cancer. In the ongoing Phase 2 trial, tumor response rates were higher than with FOLFIRI/bevacizumab alone, while median progression-free survival remained unreached as of September 28, 2026, in the proposed Phase 3 regimen.
1. FDA designation
Cardiff Oncology received FDA Fast Track designation for onvansertib with FOLFIRI/bevacizumab as a first-line treatment for adults with KRAS- or NRAS-mutated metastatic colorectal cancer. Previously reported results from the ongoing randomized Phase 2 CRDF-004 trial showed higher tumor response rates than FOLFIRI/bevacizumab alone; as of September 28, 2026, median progression-free survival remained unreached in the proposed Phase 3 regimen, compared with standard-of-care treatment. A registrational trial is planned.



